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Abstract
Background: Transformation of follicular lymphoma most typically occurs as diffuse large B-cell lymphoma, however
other forms of transformation such as classic Hodgkin lymphoma and lymphoblastic transformation can occur.
Secondary malignant histiocytosis also represents a rare form of transformation, which is thought to occur
due to a process of transdifferentiation whereby the lymphoma cells exhibit lineage plasticity and lose all
evidence of B-cell phenotype and instead acquire the phenotype of a histiocytic neoplasm. Little is known
about the underlying genetic alterations that occur during this unusual process. Comparative genetic analysis
of pre- and post-transformation/transdifferentiation would be one tool by which we could better understand
how this phenomenon occurs.
Case presentation: Here we report the clinical, immunophenotypic and genetic features of a rare case of
secondary malignant histiocytosis, Langerhans cell-type (Langerhans cell sarcoma) arising from a previous low
grade follicular lymphoma. FISH analysis confirmed the presence of IgH/BCL2 rearrangement in both the low
grade follicular lymphoma (FL) and transformed Langerhans cells sarcoma (LCS) samples, demonstrating a
clonal relationship. Comparative whole exome sequencing was then performed, which identified a KRAS p.
G13D mutation in the LCS that was not present in the FL.
Conclusions: This report highlights genetic alterations, in particular an acquired somatic KRAS mutation, that
may occur during transdifferentiation, with additional significance of KRAS mutation as a possible therapeutic
target in cases which otherwise would have limited treatment options.
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Background
Follicular lymphoma (FL) is an indolent B-cell lymph-
oma composed of follicle center B cells [1]. While gener-
ally regarded as a manageable disease with a long
survival rate, it can also progress to more aggressive
forms of lymphoma, such as diffuse large B-cell lymph-
oma. Another rare and distinct form of disease progres-
sion is transdifferentiation from a B cell neoplasm to a
neoplasm of another cell lineage [2–9]. In these
instances, the neoplastic cells demonstrate lineage
plasticity, manifested as an apparent shift in cellular
phenotype from one lineage to another while still carry-
ing shared underlying clonal genetic abnormalities. Most
reported cases have involved transdifferentiation of
chronic lymphocytic leukemia to histiocytic neoplasms
[2–4, 6, 8, 9]. Transdifferentiation is an elusive process,
and the exact pathogenic mechanisms remain unknown.
Comprehensive genetic analysis could provide a useful
tool by which to identify genetic alterations that occur
during transdifferentiation and may provide clues to the
underlying pathogenesis of this process. Furthermore, as
this form of transformation heralds a very poor progno-
sis, identification of targetable genetic mutations could
offer therapeutic options in cases where there are few
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alternatives. Here, we described a rare occurrence of a
low grade FL transdifferentiating into a Langerhans cell
sarcoma (LCS) with acquisition of KRAS mutation. As
comparative whole exome sequencing of pre- and
post-transdifferentiation lymphoma samples has not yet
been reported in the literature, this report will
contribute to the presently limited understanding of this
rare phenomenon.
Case presentation
Our patient had a long history of follicular lymphoma
which initially presented as a localized neck mass. A
biopsy of the mass showed low grade follicular lymph-
oma. The patient was treated with radiation therapy, but
3 years later, was diagnosed with diffuse large B cell
lymphoma involving lung with discordant low grade fol-
licular lymphoma in the marrow. After eight cycles of
R-CHOP therapy (rituximab, cyclophosphamide, doxo-
rubicin, vincristine, and prednisone), the patient went
into remission. Unfortunately, 6 years later, the patient
presented with skin and breast lesions as well as in-
creased adenopathy, and was treated with rituximab,
with some improvement of adenopathy. The skin nod-
ules on the left arm were noted enlarging, a subsequent
biopsy revealed low-grade follicular lymphoma, which
responded to rituximab and bendamustine therapy. A
few months later, the patient noted an enlarged inguinal
lymph node, a biopsy of which showed Langerhans cell
sarcoma. Despite 4 cycles of ICE chemotherapy and
8 weeks of ibrutinib, a PET/CT showed evidence of dis-
ease progression with diffuse intensely hypermetabolic
soft tissue nodules and lymph nodes. Biopsy of one of
the lymph nodes was consistent with diffuse large B cell
lymphoma. The patient received palliative radiation
therapy and passed away in a hospice facility. The
patient’s clinical history and treatment was summarized
in Table 1.
Histology
The initial biopsy of the mass at presentation showed
complete architectural effacement by a nodular lymph-
oid proliferation of small lymphocytes with elongated
and cleaved nuclei (Fig. 1). Flow cytometric analysis
identified a surface lambda light chain-restricted B-cell
population that was CD10+ and CD5-. Diagnosis of a
low grade follicular lymphoma was made.
Three years later, a transbronchial biopsy showed atyp-
ical mononuclear cell infiltrate composed of large cells
with large nuclei and prominent nucleoli associated with
frequent apoptotic bodies (Fig. 2). Immunohistochemical
staining showed the large cells were positive for CD20
and CD10, and exhibited a moderate proliferation rate
based on Ki-67 staining (40–50%). These findings were
consistent with diffuse large B-cell lymphoma. A concur-
rent bone marrow biopsy showed a paratrabecular
lymphoid infiltrate composed of small centrocytes con-
sistent with involvement by follicular lymphoma (Fig. 2).
Flow cytometric analysis identified a monotypic, surface
lambda light chain-restricted B-cell population that was
dim CD10+ and CD5-, supporting involvement by fol-
licular lymphoma.
The breast biopsy showed an abnormal lymphoid
infiltrate composed predominantly of small lympho-
cytes with elongated nuclei and condensed chromatin.
The abnormal lymphocytes were CD20+, CD10+,
BCL-6+ and BCL-2+, consistent with recurrent fol-
licular lymphoma (Fig. 3). A few months later, an en-
larged inguinal lymph node showed effacement of
architecture by an abnormal polymorphous infiltrate
composed of many highly atypical large cells with
admixed histiocytes, small lymphocytes, neutrophils,
Table 1 Summary of Clinical, Pathologic and Genetic Characteristics of Tumors
Timeline Location Diagnosis Immunophenotype of Neoplastic Cells Key FISH/Molecular
Characteristics
Therapy
Year 1 Neck mass FL (Fig. 1) CD19+, CD10+, CD5-, surface lambda
restricted
NA Radiation
Year 3 Lung and bone
marrow
Lung: DLBCL
Bone marrow:
FL (Fig. 2)
Lung: CD20+, CD10+
Bone marrow: CD19+, CD10+, CD5-,
surface lambda restricted
NA R-CHOP
Year 9 Skin and breast FL (Fig. 3) CD20+, CD10+, BCL6+, BCL2+ IgH/BCL2 fusion
KRAS wildtype
MYC extra copies; no MYC
rearrangement
R-Bendamustine
Year 10 Inguinal lymph
node
LCS (Fig. 4) CD45+, CD43+, CD1a+, S100+, CD20-, PAX5-,
CD19-, CD79a-, CD10-, BCL6+ (focal)
IgH/BCL2 fusion
KRAS p.G13D
MYC extra copies;
no MYC rearrangement
ICE, ibrutinib
Year 10 Ear mass DLBCL CD20+, CD10+, CD1a-, S100- NA Palliative radiation
therapy
FL Follicular Lymphoma, LCS Langerhans Cell Sarcoma, DLBCL Diffuse Large B cell Lymphoma, NA Tissue Not Available
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eosinophils and rare plasma cells (Fig. 4). The large
pleomorphic cells had deeply convoluted nuclei and
abundant cytoplasm. Immunohistochemical stains
showed the large cells were positive for CD45, CD43,
CD1a, and S-100. CD20 and PAX5 immunostains
showed virtually no B cells present in the lesion. Flow
cytometric analysis did not identify a distinct CD19+
B-cell population. The findings were consistent with
Langerhans cell sarcoma.
FISH analysis
To establish the genetic relationship between the LCS
and the patient’s prior FL, FISH analysis for t(14;18)
BCL2/IgH was performed on the touch imprints of the
recurrent breast follicular lymphoma and LCS. FISH
analysis revealed the presence of t(14;18) BCL2/IgH fu-
sion signals in 62% and 21% of the 200 cells analyzed in
follicular lymphoma and LCS respectively (Fig. 3 and
Fig. 5). In LCS, the fusion signal is only present within
Fig. 1 Diagnostic low grade follicular lymphoma. Excisional biopsy reveals a nodular lymphoid proliferation of small lymphocytes with elongated
nuclei (a H&E, 100X; b H&E, 600X). Flow cytometric analysis identifies a surface lambda light chain-restricted B-cell population that is CD10+ and CD5-
Fig. 2 Diffuse large B-cell lymphoma. A transbronchial biopsy of the lung mass shows a diffuse proliferation of CD20+ large cells with large
nuclei, open chromatic, occasional nucleoli associated with frequent apoptotic bodies (a H&E, 600X; b CD20 IHC, 600X). A bone marrow core
biopsy shows an abnormal paratrabecular lymphoid infiltrate comprising of small lymphocytes with elongated nuclei (c H&E, 200X; d H&E, 600X).
Flow cytometric analysis of the bone marrow aspirate (not shown) identified a monotypic, surface lambda light chain-restricted B-cell population
that was dim CD10+ and CD5-, consistent with bone marrow involvement by follicular lymphoma
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the sarcoma cells identified by their enlarged size and bi-
zarre nuclear morphology, but not in any background
inflammatory cells. And almost all the sarcoma cells har-
bor this translocation. Interestingly, the sarcoma cells
displayed 4–5 copies of IgH/BCL2, indicating amplifica-
tion of fusion signals from t(14:18) (Fig. 5). Using MYC
break apart probes, both FL and Langerhans cell sar-
coma sample were negative for MYC rearrangement;
however, extra MYC signals were seen in 21% and 22%
of the 200 cells analyzed in FL and LCS respectively, and
in latter only present in the sarcoma cells. Molecular
analysis was performed on the bone marrow aspirate
with involvement of follicular lymphoma. The result was
positive for clonal IGH gene rearrangement with 334 bp,
273 bp and 133 bp clonal bands by FR1, FR2 and FR3
biomed primers. Molecular analysis was also performed
on the LCS and was negative for clonal immunoglobulin
heavy chain rearrangement.
Molecular analysis and whole exome sequencing
Additional molecular analysis for BRAF V600E muta-
tion, which has been reported in 38–57% of Langerhans
cell histiocytosis but not as of yet in any cases of
Langerhans cell sarcoma [1, 10, 11], and was negative
for this mutation.
Comparative whole exome sequencing was performed
on paraffin-embedded tissue sections from the breast
low-grade follicular lymphoma sample and Langerhans
cell sarcoma sample. The tumor burden was estimated
at 90% and 20–30% with median depth of read of 140
and 92 for the follicular lymphoma and Langerhans cell
sarcoma samples, respectively. After filtering, there were
12 variants including 10 nonsynonymous SNVs and two
inframe mutations shared by both the FL and LCS. The
majority of SNVs, which had a variant allele frequency
(VAF) close to 0.5 in both samples or had alternative
allele frequency above or close to 0.01 in the 1000 g or
ExAC database, may represent germline polymorphisms
(Table 2, Additional file 1: Table S1). The shared
CREBBP mutation (NM_001079846:exon29:c.4920_
4922del:p.1640_1641del) has a VAF lower than other
shared variants (0.31 in FL and 0.23 in LCS), and may
represent a shared somatically acquired driver mutation.
CREBBP is a histone modifier that is frequently mutated
in FL [12, 13].
Twelve variants were present in the FL but not in the
LCS. After filtering, there were 4 remaining nonsynon-
ymous SNVs, 1 stopgain, and 3 inframe deletions (Table 2,
Additional file 2: Table S2). Included among these variants
were KMT2D p.R5097* and BCL2 p.S203 N, which have
been previously identified in FL [14, 15].
Fig. 3 Recurrent low grade follicular lymphoma. A needle core biopsy reveals an abnormal infiltrate of small lymphocytes that are predominantly
CD20+ B cells with coexpression of CD10, BCL6 and BCL2, consistent with low grade follicular lymphoma (a H&E, 200X, b CD20 IHC, 200X; c
CD10, 200X, d BCL2 IHC, 200X). Dual color dual fusion FISH analysis confirms the presence of IgH/BCL2 fusion signals resulting from t(14;18) in
62% of cells analyzed (Inset)
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Although copy number alterations were not covered
in this assay, analysis of allele frequency of commonly
occurring SNVs can be a useful indicator of loss of
heterozygosity (LOH). There were 14 nonsynonymous
single nucleotide variants demonstrating potential
LOH (i.e. heterozygous in the FL and homozygous in
the LCS). None of the variants were considered
deleterious (Table 2, Additional file 3: Table S3).
Thirty variants were identified in the LCS sample
that were not present in the FL sample including 26
nonsynonymous SNVs, 2 frameshift insertions and 2
inframe deletions. After filtering out of benign or
likely benign variants, the remaining variants included
11 nonsynonymous SNVs, 2 frameshift insertions and
2 inframe deletions (Table 2, Additional file 4: Table
S4). Most of the variants were of unknown signifi-
cance, except KRAS p.G13D (Fig. 6), which is a
well-known pathogenic variant in a variety of malig-
nancies including carcinoma and hematopoietic neo-
plasms [16–18]. To confirm the presence of KRAS
mutation, a real-time PCR analysis was also performed
in both the FL and LCS. The results confirmed the
presence of KRAS p.G13D in the LCS but not in the
FL (data not shown).
SNP microarray analysis
Multiple chromosomal abnormalities were identified in
the follicular lymphoma sample which include 6p
CN-LOH, 6q deletion, small gain at 7p, 9p21.3 deletion
(CDKN2A/2B genes included), small deletion at 10q,
Fig. 4 Langerhans cell sarcoma. The inguinal lymph node biopsy shows a complete effacement of the lymph node architecture by an abnormal
polymorphous infiltrate of histiocytes, small lymphocytes, neutrophils, eosinophils and rare plasma cells, with scattered and focal sheets of
atypical large cells with convoluted nuclei (a H&E, 100X, b H&E, 600X). The large cells are CD1a + and S100+ (c CD1a IHC, 600X; d S100 IHC, 600X).
The morphology and phenotype is consistent with a diagnosis of Langerhans cell sarcoma. The large cells were CD20-, CD19- (not shown), PAX5-
(not shown) and CD10- (e CD20 IHC, 600X; f CD10 IHC, 600X)
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small deletion at 12q (distal breakpoint within BCL7A
gene), 16p deletion, small 16p gain, 2 CN-LOHs on 20p
and some gains involving 20p, a homozygous loss in-
volving chromosome 22q11.22 involving the IGL gene
and likely related to gene rearrangements in the tumor,
a CNV gain involving chromosome 22q11.23 and gain
of entire chromosome X (Table 3). However, there were
no significant abnormalities identified in the Langer-
hans cell sarcoma sample with the exception of KRAS
p. G13D and a CNV gain on chromosome 22q11.23,
which was also observed in the follicular lymphoma
sample (Table 3).
Fig. 5 Dual color dual fusion FISH analysis demonstrates multiple IgH/BCL2 fusion signals resulting from t(14;18) in 21% of cells analyzed. The
fusion signals are present only in the large sarcoma cells with but not in any of background inflammatory cells
Table 2 Summary of Variants with Possible or Unknown Significance Present in Follicular Lymphoma or/and Langerhans Cell
Sarcoma
Variants Shared in FL and LCS Variants present only in FL Variants present only in LCS
10 nonsynonymous SNVs
SPEN p.K1064I
PDE4DIP p.R1867C
PDE4DIP p.E573V
PDE4DIP p.S438 L
PDE4DIP p.A127T
ARHGAP26 p.R293W
PMS2 p.I18V
ATM p.S49C
KMT2D p.P1131L
SPECC1 p.D688N
4 nonsynonymous SNVs
IL2 p.V89 L
CDKN2A p.M1T
BCL2 p.S203 N
BCL2 p.A45T
SMARCA4 p.G883D
11 nonsynonymous SNVs
BIN1 p.H283Y
TMEM200A p.G383R
DNAJB12 p.R13W
KRAS p.G13D
TRPV42 p.R249H
ADAD2 p.R299Q
KRTAP4–7 p.S113C
EMR2 p.C520F
ARMCX4 p.G1814E
ARMCX4 p.E1816G
ARMCX4 p.G1820E
2 inframe deletions
ZNF384 p.385_385del
CREBBP p.1640_1641del
1 stopgain
KMT2D p.R5097X
2 frameshift insertions
CAMTA1 p.N1271 fs
BCR p.G1049 fs
3 inframe deletions
MLLT3
MN1 p.524_524del
MN1 p.304_304del
2 inframe deletions
ARID1A p.1333_1334del
NOTCH1 p.2411_2411del
Choi et al. Diagnostic Pathology  (2018) 13:78 Page 6 of 13
Discussion and conclusions
Classification of hematopoietic neoplasms is predicated
on the assumption that the phenotype of a neoplastic
cell is intrinsically linked to a predefined lineage and
that this lineage determines the type and nature of the
neoplasm. However, as demonstrated in cases of trans-
differentiation, these associations are not hard and fast
rules, as cells, both physiologic and neoplastic, can dem-
onstrate lineage plasticity [3–9, 19–21]. Our patient’s
pathologic studies include a wide range of morphologic
variation in the neoplastic clone, ranging from low grade
FL to DLBCL to later on, LCS.
The mechanisms by which transdifferentiation occurs
are largely unknown and previously described cases have
relied upon molecular clonality or other genetic markers
to establish a clonal relationship between what otherwise
would appear as two phenotypically distinct neoplasms.
Clonal IgH rearrangements have been reported in 39%
of sporadic cases of histiocytic/dendritic cell sarcomas
[22] which may reflect the close relationship and pos-
sible common precursor between neoplasms of histio-
cytic differentiation and lymphoid differentiation [4, 6, 7,
9, 19, 23–25]. In our case, while a clonal IgH rearrange-
ment was detected in the FL from the fresh bone mar-
row sample, PCR analysis failed to identify a clonal IgH
rearrangement in LCS. The reason for the absence of
clonal IgH rearrangement in the LCS sample is not en-
tirely clear, but could be due to additional genetic alter-
ations affecting the specific binding of the PCR primers
or decreased assay sensitivity in formalin fixed tissue.
However, the clonal relationship between FL and LCS
was definitively confirmed by FISH analysis, which able
to readily identify the t(14;18), IgH/BCL2 within
morphologically-apparent sarcoma cells. The shared
t(14;18), IGH/BCL2 translocation in both the follicular
lymphoma and LCS by FISH provided strong evidence
Fig. 6 Exome sequencing performed on the Langerhans cell sarcoma sample revealed a G13D mutation results in an amino acid substitution at
position 13 in KRAS, from a glycine to an aspartic acid (Variant allele frequency: 0.24) (b). This KRAS p.G13D mutation was not present in the
previous follicular lymphoma (a)
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of their clonal relationship, as this translocation is con-
sidered very specific for follicular lymphoma and has not
been reported in any de novo sarcoma.
The shared CREBBP mutation (NM_001079846:ex-
on29:c.4920_4922del:p.1640_1641del) is an interesting
finding. CREBBP mutations, particularly mutations of
the acetyltransferase domain, has been implicated as an
early driver event in follicular lymphoma [26, 27].
Although the specific CREBBP mutation that we have
detected in this case has not been previously reported in
COSMIC database, it does occur within this functional
acetyltransferase domain (p.1342-p.1649) [28, 29]. Thus,
it could potentially represent a shared acquired somatic
driver mutation and further support a model of direct
transdifferentiation of LCS from antecedent follicular
lymphoma rather than, for example, evolution from a
common precursor neoplastic cell harboring an early
translocation t(14;18) event.
The additional SNP microarray results also suggest
that the LCS likely originated from an earlier follicular
lymphoma with t(14;18). As the LCS does not share the
other complex genetic alterations with the exception of
the shared CNV gain involving 22q11.23. However, it is
worth pointing out that the LCS sample contains rela-
tively low tumor burden (20–30% by visual estimation)
with a dense background of inflammatory cells, whereas
the follicular lymphoma contains almost 100% tumor
cells. Therefore, other more subtle genetic alterations in
the sarcoma cells may not be identified by the
OncoScan SNP microarray which requires at least
25% tumor content.
The most intriguing finding in this case is the detec-
tion of KRAS p. G13D, a known pathogenic mutation,
detected solely in the LCS sample. RAS mutations have
been implicated in a number of hematologic malignan-
cies, with NRAS mutations being more prevalent than
KRAS mutations, particularly in myeloid neoplasms [30].
RAS-MAPK alterations have also been frequently de-
scribed in hairy cell leukemia and multiple myeloma, but
are more rarely seen in other lymphoproliferative disor-
ders, such as diffuse large B-cell lymphoma [31, 32]. In
studies analyzing mutational profiles of follicular lymph-
oma, a pathogenic role for RAS mutation in the
development of follicular lymphoma has not been
described [33, 34], although it has been reported as a
rare event in cases of histologic transformation [35].
In a study of 55 primary DLBCL samples, KRAS
p.G13D mutation was identified in 2 cases, thus is it
possible that RAS mutations could drive the patho-
genesis of a relatively rare subset of primary and sec-
ondary DLBCL [32]. A separate study described
differential gene expression of genes in the MAPK
signaling pathway, including NRAS, in cases of fol-
licular lymphoma compared with transformed follicu-
lar lymphoma, suggesting activation of this pathway
could be important in disease transformation [36]. In
our case, the KRAS p.G13D may have arisen during
the transformation process. Further studies to com-
pletely delineate clonal derivation were desired but
precluded by the absence of material from original FL
and subsequent DLBCL for additional testing. None-
theless, the high prevalence of KRAS p.G13D
Table 3 Chromosomal abnormalities in Follicular lymphoma and Langerhans cell sarcoma detected by SNP microarray
Sample Type Chromosome Cytoband Size (Mb) Comment
Follicular Lymphoma Loss 6 q11.1-q27 109.02
9 p21 0.74 CDKN2A gene
10 q24.1 1.43
16 p13.3-p13.12 14.25
Homozygous loss 22q q11.22 0.5 IGL gene
Gain 7 p21.1-p15.3 4.18
16 p11.2 1.01
20 p12.2-p12.1 4.52
20 p11.23-q13.33 44.31
X p22.33-q28 155.27 Whole chromosome gain
High copy gain 22 q11.23 0.05 CNV
CN-LOH 6 p25.3-p11.1 58.73
20 p13-p12.2 9.45
20 p12.1-p11.23 5.06
Langerhans cell sarcoma Point mutation 12 p12.1 – p.G13D
c.38G > A
High copy gain 22 q11.23 0.05 CNV
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mutation in the sarcoma cells, inferred from a variant
allele frequency similar to the sarcoma tumor burden,
suggests that it is a predominant mutation within the
sarcoma cells.
Our finding raises a couple of important questions.
What is the significance of KRAS mutation in histiocytic
neoplasms? Could this mutation potentially drive trans-
differentiation process itself? A recent abstract presenta-
tion [37] retrospectively reviewed cases of histiocytic
sarcomas and discovered RAS/MAPK mutations in 44%
(n = 8) of cases. KRAS p.G13D was present in 3 of the
cases. Some of the cases of histiocytic sarcoma also pos-
sessed mutations that are common in B-cell lymphoma
(such as MYD88, SOCS1, KMT2D, ARID1A) and fur-
thermore, a subset of patients with histiocytic sarcoma
had concurrent or prior history of B-cell lymphoma, in-
cluding follicular lymphoma, which raised the possibility
of transdifferentiation. This suggests that RAS/MAPK
mutations are actually quite common in histiocytic neo-
plasms, even some that may be secondary to B-cell
lymphoma, and that given their prevalence, may actively
participate in driving this disease process.
In terms of Langerhans cell neoplasms, the RAS/
MAPK signaling pathway has been strongly implicated
as a pathogenic driver. Recent mouse models have dem-
onstrated that expression of KRAS p.G12D mutation in
lung myeloid cells induce the development of pulmonary
Langerhans cell histiocytosis (LCH) [38]. NRAS p.Q61K
mutations have also been reported at higher frequency
in cases of pulmonary LCH [39], but have not thus far
been seen in non-pulmonary cases. A study of 61 cases
of non-pulmonary LCH reported BRAF V600E muta-
tions in half of cases, also detected several other point
mutations including TP53 p.R175H, KRAS p.G13D and
MET p.E168D [10]. BRAF is an essential component of
the RAS-RAF-MEK-ERK signaling cascade, which is
triggered by binding of extracellular growth factor or cy-
tokines to surface tyrosine kinase receptors, eventually
leading to the modulation of downstream gene expres-
sion [40]. The activation of this pathway in LCH is fur-
ther supported by the fact that MEK and ERK
phosphorylation could be detected by immunohisto-
chemistry in all cases of LCH, regardless of BRAF muta-
tional status [41]. Activating mutations in BRAF other
than V600E have also been detected in LCH [42–44].
Furthermore, cases without BRAF V600E mutation have
demonstrated a high prevalence of somatic MAP2K1
mutation, which are mutually exclusive with BRAF mu-
tations [43, 45]. Thus, there is a substantial amount of
evidence to suggest that the RAS-RAF-MEK-ERK signal-
ing pathways is important to the evolution of LCH.
LCS is an extremely rare malignancy thought to be
derived from Langerhans histiocytes, and because of the
scarcity of reported cases, the molecular pathogenesis of
this entity is mostly unknown. However, it is not unrea-
sonable to infer that some of the same pathways that
drive LCH could also drive LCS. Interestingly, a recent
report of histiocytic sarcoma transdifferentiation from
B-lymphoblastic leukemia demonstrated NRAS p.G12D
mutation, further suggesting RAS pathway alterations
may be important in the transdifferentiation process
[46]. It is also possible that other genetic or epigenetic
changes which are as yet uncharacterized may contribute
to lineage conversion and phenotypic switch seen during
transdifferentiation.
Because of its prevalent role in neoplasms of multiple
different organ systems, the RAS-RAF-MEK-ERK signal-
ing pathway is also a target for novel therapeutics,
including monoclonal antibodies and small molecule in-
hibitors, for example BRAF and MEK inhibitors in mel-
anoma [47–49]. KRAS is one integral component of the
RAS-RAF-MEK-ERK signaling pathway that acts
upstream of BRAF [50]. Detection of KRAS mutation is
now recommended in colorectal carcinoma, since its
presence indicates resistance to targeted therapy against
upstream signaling proteins (i.e. EGFR) [51]. Recent
studies have shown specific efficacy of cetuximab in
colorectal cancer patients with KRAS p.G13D mutations
(the same mutation detected in our patient) and not
other KRAS mutations [52, 53]. Ongoing studies in a
variety of neoplasms examining RAS proteins and other
downstream mediators, such as BRAF and MEK, as
druggable targets offer additional therapeutic possibil-
ities in patients with applicable genetic alterations, such
as the current case [54–56].
It is important to recognize that while the results of
whole exome sequencing in this case suggest complex
genetic reprogramming may occur during the transdif-
ferentiation process, this method may fail to identify all
possible genetic abnormalities, including splice variants
or chromosomal gains/losses. As such, additional genetic
events may play a cooperative role in developing this ag-
gressive disease. However, the detection of an activating
KRAS mutation, which is not typically associated with
B-cell lymphoma, combined with the growing body of
evidence that this signaling pathway is essential to the
development of Langerhans cell neoplasms, suggests
that acquisition of this mutation could potentially drive
or influence transdifferentiation.
In summary, this case describes transformation/trans-
differentiation of a low grade FL into a LCS with detec-
tion of KRAS p.G13D mutation in the transformed
sample. Our findings demonstrate characterize genetic
events that may occur during transdifferentiation and
further emphasizes the role of alterations of
RAS-RAF-MEK-ERK signaling in the pathogenesis of
Langerhans cell neoplasms. Importantly, the discovery of
acquired KRAS mutation raises the possibility of targeted
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therapies (e.g. small molecule inhibitors) [50, 57] in the
treatment of patients with these neoplasms who other-
wise have limited therapeutic options.
Materials and methods
Pathology review
H&E sections from the patient’s previous biopsies were
retrieved from the Department of Pathology at North-
western Memorial Hospital. The available archival mate-
rials were reviewed, along with associated ancillary
studies, including immunohistochemical stains per-
formed at the time of diagnosis, flow cytometric analysis
and molecular analysis. Additional immunohistochemi-
cal stains, molecular and fluorescence in situ
hybridization (FISH) analysis were performed in this
study and are further described.
Immunohistochemistry
Immunohistochemical staining was performed on
formalin-fixed, paraffin-embedded tissue. Antigen retrieval
and immunohistochemical stain were performed on an
automated immunostainer following the manufacturer’s
protocol (Ventana Medical Systems, Tuczon, AZ). The fol-
lowing predilute antibodies were used: CD3 (Ventana),
BCL-2 (Cell Marque, Rocklin, CA), BCL-6 (Cell Marque),
Ki-67 (Ventana), CD43 (Ventana), CD1a (Beckman Coulter,
Miami, FL), S-100 (Ventana). The following antibodies
were also used: CD20 (Dako, Carpinteria, CA), Pax-5 (1:10,
Cell Marque), CD10 (1:30, Leica, Buffalo Grove, IL), CD45
(1:300, Dako). Positive and negative controls were per-
formed with all cases and showed appropriate staining.
Fluorescence in-situ hybridization (FISH)
Interphase FISH with Vysis dual color break-apart
MYC (8q24), and dual color break-apart BCL2
(18q21) probes (Abbott Molecular Inc., Des Plaines,
IL) were performed on paraffin-embedded tissue sec-
tions. The 5′ and 3′ portions of the MYC and BCL2
probes are labeled with SpectrumOrange and Spec-
trumGreen, respectively. Interphase FISH analysis
with Vysis dual color dual fusion IGH (14q32) and
BCL2 (18q21) probes were performed on the lymph
node touch imprints. Negative and positive control
slides were performed in parallel with the patient
sample in the same hybridization process. A total of
100 interphase cells were evaluated for MYC and
BCL2 rearrangement independently by two laboratory
technologists. An abnormal result was determined if
the percentage of cells with abnormal FISH signals
(i.e. separation of the 5′ and 3’ MYC and BCL2
probes due to a translocation or abnormal FISH sig-
nal patterns due to fusions) was above the relevant
cut-off values at 95% confidence.
Immunoglobulin heavy chain (IGH) clonality assay
Molecular analyses were performed to assess for the
presence of clonal IGH rearrangements. DNA was
extracted from fresh bone marrow aspirate or
formalin-fixed, paraffin-embedded tissue sections. DNA
extraction and purification was performed on automated
nucleic extraction instrument QIAsymphony SP using
QIAsymphony DNA Mini Kit (Qiagen, Valencia, CA).
Multiplex PCR-based clonality assays were performed
following manufacturers’ protocols (Invivoscribe, San
Diego, CA, USA). The PCR products are detected by
capillary gel electrophoresis on an ABI 3130XL genetic
analyzer (Applied Biosystems, Foster City, CA, USA).
An amplification band was considered clonal if the
height of the peak was more than 3 times the height of
the third highest peak in a given range of DNA sizes.
BRAF V600E mutational analysis
Analysis of BRAF V600E mutation was performed using
COBAS 4800 BRAF Mutation assay according to the
manufacturer’s protocol (Roche Molecular Diagnostics).
The results were reported as follows: i) V600E mutation
detected, ii) V600E mutation not detected, or iii) invalid
(ie, no result was obtained on the COBAS test). The
COBAS BRAF Mutation assay can detect the BRAF
V600E mutation at greater than 5% mutation level.
Whole exome sequencing
Whole exome sequencing was performed at the UCLA
Technology Center for Genomics & Bioinformatics.
DNA was extracted from the formalin fixed paraffin
embedded tissue sections from both the breast biopsy
and inguinal lymph node. The library construction was
performed using the SeqCap EZ System from Nimble-
Gen (Roche NimbleGen, Inc. Madison, WI) according to
the manufacturer’s instructions. Briefly, genomic DNA
was sheared, size selected to roughly 300 base pairs, and
the ends were repaired and ligated to specific adapters
and multiplexing indexes. Fragments were then incu-
bated with SeqCap biotinylated DNA baits after
LM-PCR and the hybrids were purified using
streptavidin-coated magnetic beads. After amplification
of 18 or less PCR cycles, the libraries were then se-
quenced on the HiSeq 3000 platform from Illumina,
using 100-bp pair-ended reads.
The sequence data were aligned to the GRCh37 hu-
man reference genome using BWA v0.7.7-r411. PCR du-
plicates were marked using MarkDuplicates program in
Picard-tools-1.115 tool set. GATK v3.2–2 was used for
INDEL (insertions and deletions) realignment and base
quality recalibration. Exome coverage was calculated
using the bedtools. Samtools was used to call the SNVs
(single nucleotide variants) and small INDELs. Varscan2
was used to call the somatic SNVs. All variants were
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annotated using the Annovar program. Copy number al-
terations and structural variants were not covered in this
assay. The variants were ranked by SIFT and PolyPhen
scores. A variant with SIFT score < 0.05 is predicted as
deleterious (D), otherwise is tolerated (T). A variant with
Polyphen score > 0.9 is predicted probably damaging, <
0.45 is predicted benign, between 0.45 and 0.9 is pre-
dicted possibly damaging. Variants were filtered out
based on allele frequency of > 1% reported in 1000Gen-
ome, exAC (The Exome Aggregation Consortium); mini-
mum read-depth of 30; any variants that were in the
UTR or upstream/downstream of the gene; variants with
a synonymous coding effect and variants within intronic
region, unless they result in splice site mutations. Vari-
ants of 100% allele frequency in both tissues were con-
sidered germline and not included.
KRAS mutational analysis
Evaluation of KRAS mutational status was performed
using the KRAS Mutation real-time PCR Analysis Kit
(EntroGen, Tarzana, CA, USA) following the manufac-
turer’s protocol. This assay employs allele-specific
primers that are complementary to mutant variants of
the KRAS genes. Detection of the amplification products
was performed with the use of fluorescent hydrolysis
probes. Probes tagged with the FAM fluorophore were
complementary to the targets of KRAS genes. This assay
identifies the following mutations in codon 12: G12S,
G12D, G12V, G12C, G12A, G12R; in codon 13: G13D;
and in codon 61: Q61H (61CAA > CAT), Q61L, Q61R,
Q61H (61CAA > CAC).
Single nucleotide polymorphism (SNP) microarray
analysis
SNP microarray analysis was performed using the
OncoScan FFPE Express 3.0 assay kit (Affymetrix, Santa
Clara, CA) as per manufacturer’s recommendation. The
assay utilizes Molecular Inversion Probe (MIP) technol-
ogy, which is optimized for highly degraded FFPE sam-
ples (probe interrogation site of just 40 base pairs) (1–3).
The assay employs 220,000 SNP MIP probes which
ensure a resolution of 50–100 kb in selected genomic re-
gions covering 900 cancer genes and of 300 kb outside
of these regions. Briefly, 10 unstained FFPE tissue sec-
tions cut at 10 μM were obtained and tumor was macro-
dissected using a hematoxylin and eosin -stained slide as
a guide. DNA was extracted and purified from the sam-
ples using the QIAmp DNA FFPE Tissue Kit (Qiagen,
Dusseldorf, Germany) according to the manufacturer’s
protocols. Extracted DNA was quantified using the
Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen,
Carlsbad, CA, USA) following the manufacturer’s proto-
col. A total of 80 ng of DNA from each sample was
annealed to the MIP probe panel. Annealed MIPs were
circularized, followed by enzymatic removal of any
un-ligated probe and template DNA. Remaining MIPs
were linearized, amplified, enzymatically fragmented,
and hybridized to oligonucleotide microarrays. The ar-
rays were washed, scanned, and the results were ana-
lyzed and interpreted using OncoScan Console and
Nexus Express for OncoScan 3 software (BioDiscovery,
El Segundo, CA, USA) as previously described [58–60].
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